Diabetes

NIH awards company phase II SBIR grant to study diabetes

Published in Obesity and Diabetes Week, May 17th, 2004

Adenosine Therapeutics, LLC, (ATL) announced the award of a phase II small business innovation research (SBIR) grant from the U.S. National Institutes of Health.

The grant will fund research to identify an oral therapeutic candidate for the treatment of type II diabetes. The amount of the award is $1,384,444 over a 2-year period.

"Our research has determined that ATL compounds which block adenosine receptors lower blood glucose in rats and mice. The focus of the research funded by this grant will expand testing on a new family of compounds that are expected to be more efficacious than previous compounds," said Joel Linden, PhD, cofounder of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2004-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry